KalVista Pharma

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.co

KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content:   KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824.

FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). “The execution of KOMPLETE, our Phase 2 clinical

KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE). “Over the past month we have made substantial progress in commencing KOMPLETE, our worldwide Phase 2 clinical tria

KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV #EAACI2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data presented for its oral drug candidates at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. Data presentations include a late-breaking poster for the Phase 2 data for KVD900, KalVista's lead drug program for ora

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc. (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate KalVista Pharmaceuticals, Inc. (KALV) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, from July 10-12, 2021. The details are as follows: Title: A single on-demand treatment with orally administered KVD900 significant

KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the oral presentation of clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. “Our goal is to provide the best outcome for HAE patients

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio ar

KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an abstract for KVD900 as an oral presentation at the 12th C1-Inhibitor Deficiency & Angioedema Workshop, which will be held virtually from June 3-6, 2021. The presentation details are as follows: Title: Fast improvement o

KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. “As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage dru

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

Syndax Pharmaceuticals

CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Rises On Gene Editing Therapy Pact With Vertex: CRISPR announced an amended collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with respect to CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Why Crispr, KalVista And Syndax Are Moving Today

Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare genetic disorder hereditary angioedema (HAE), the FDA has issued a hold on their Phase 2 study of KVD824, an oral drug to prevent HAE. The FDA letter requests further information and analysis related to certain preclinical studies of KVD824 submitted to support the planned Phase 2 trial.

KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has notified the Company in a letter that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824. KVD824 is KalVista's oral product candidate being developed for proph

KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and bus

KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

KalVista Pharmaceuticals, Inc. (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the Upgrade

KalVista Pharmaceuticals, Inc. (KALV) delivered earnings and revenue surprises of 6.67% and -100.00%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?

KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates

KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista's common stock. After giving effect to the full exercise of the

KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offered 4.5 million shares.

KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriter

KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock

Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?

Can KalVista Pharmaceuticals Stock Fly Higher?

Analysts say the biotech's investors could be in store for even more gains.

Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today

Do favorable results in a mid-stage drug trial justify the stock of the developer more than doubling in a day?

KalVista Shares More Than Double on Drug Test Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions. All of the shares will be offered and sold by KalVi

News for KalVista Pharma Stock (KALV)